Serotonin 2A receptors and visual hallucinations in Parkinson disease

Archives of Neurology

Volumn 67, Issue 4, 2010, Pages 416-421

  Ballanger, Benedicte ^a   Strafella, Antonio P ^a,b   Van Eimeren, Thilo ^a   Zurowski, Mateusz ^a   Rusjan, Pablo M ^a   Houle, Sylvain ^a   Fox, Susan H ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 2A RECEPTOR; SETOPERONE;

AGED; ARTICLE; BRAIN REGION; CASE CONTROL STUDY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUSIFORM GYRUS; HUMAN; INSULA; LEFT HEMISPHERE; MALE; NEUROTRANSMISSION; OCCIPITAL LOBE; ORBITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RIGHT HEMISPHERE; TEMPORAL CORTEX; VISUAL HALLUCINATION;

AGED; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINONES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN ANTAGONISTS; TEMPORAL LOBE; VISUAL CORTEX; VISUAL PATHWAYS;

EID: 77950894522     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.35     Document Type: Article

References (28)

1. Manford M, Andermann F. Complex visual hallucinations: clinical and neurobiological insights. Brain. 1998;121(pt 10):1819-1840. (Pubitemid 28454354)
2. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand. 1991;84(2):111-113.
3. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21(2)(suppl):16S-23S.
4. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73. (Pubitemid 26112775)
5. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369.
6. Blin J, Pappata S, Kiyosawa M, Crouzel C, Baron JC. [18F]Setoperone: a new highaffinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol. 1988;147(1):73-82. (Pubitemid 18058727)
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314. (Pubitemid 24382728)
9. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982;139(4):494-497. (Pubitemid 12141048)
10. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007;22(8):1077-1092. (Pubitemid 47067217)
11. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183-189, 313. (Pubitemid 351311545)
12. Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the Mini-Mental State exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord. 2008;23(2):297-299. (Pubitemid 351311567)
13. Maziere B, Crouzel C, Venet M, et al. Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors. Int J Rad Appl Instrum B. 1988;15(4):463-468.
14. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4):279-287.
15. Fischman AJ, Bonab AA, Babich JW, et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther. 1996;279(2):939-947.
16. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-745. (Pubitemid 30162723)
17. Kanwisher N, Chun MM, McDermott J, Ledden PJ. Functional imaging of human visual recognition. Brain Res Cogn Brain Res. 1996;5(1-2):55-67. (Pubitemid 27095237)
18. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727-733. (Pubitemid 32554201)
19. Haxby JV, Horwitz B, Ungerleider LG, Maisog JM, Pietrini P, Grady CL. The functional organization of human extrastriate cortex: a PET-rCBF study of selective attention to faces and locations. J Neurosci. 1994;14(11, pt 1):6336-6353. (Pubitemid 24333057)
20. Grill-Spector K, Sayres R, Ress D. High-resolution imaging reveals highly selective nonface clusters in the fusiform face area. Nat Neurosci. 2006;9(9):1177-1185. (Pubitemid 44306312)
21. Middleton FA, Strick PL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci U S A. 1996;93(16):8683-8687.
22. Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord. 2000;15(6):1064-1069.
23. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci. 1998;861:288-289. (Pubitemid 29047755)
24. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65(11):1708-1715. (Pubitemid 43754398)
25. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63(8):1409-1416.
26. Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64(7):984-988. (Pubitemid 47047998)
27. Silbersweig D, Stern E. Functional neuroimaging of hallucinations in schizophrenia: toward an integration of bottom-up and top-down approaches. Mol Psychiatry. 1996;1(5):367-375. (Pubitemid 126441319)
28. Allen P, Larøi F, McGuire PK, Aleman A. The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev. 2008;32(1):175-191. (Pubitemid 350160963)